Plasma Hepcidin as a Prognostic Biomarker in Obese and Nonobese Patients With Early Breast Cancer: A Pooled Analysis of Two Prospective Cohort Studies
Clinical Breast Cancer · 2026-05 · 26 (5) · 29-35
DOI: 10.1016/j.clbc.2026.03.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026-05. Verfasst von Evan Cescon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Hepcidins, Breast Neoplasms, Obesity, Biomarkers, Tumor. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
PURPOSE To evaluate whether elevated baseline plasma hepcidin is associated with shorter time to distant recurrence (TTDR) and overall survival (OS) in women with obesity who are diagnosed with early-stage breast cancer (BC). METHODS We performed a pooled analysis of individual patient data within two prospective cohort studies, the "Canadian" (n = 518) and "French" (n = 144) cohorts. Plasma hepcidin levels were measured postoperatively and prior to systemic therapy initiation. Cox regression models were fitted to each data set, treating hepcidin as a continuous variable and with a hepcidin-by-body mass index (BMI; kg/m2) interaction (BMI dichotomized at 30). Cohort-specific "beta" coefficients and standard errors from each survival model were combined meta-analytically using a random effect model, with results presented as hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS In total, 662 patients were included; the median age was 48.6 years across both cohorts. Most patients (89%) had T1 or T2 tumors, and approximately two-thirds had lymph node-negative disease (69.9% Canadian; 52.8% French). In total, 16.4% and 16.0% of patients in the Canadian and French cohorts were obese (BMI ≥ 30). In our pooled analysis, elevated plasma hepcidin was significantly associated with shorter TTDR (adjusted HR 2.27; 95% CI, 1.26-4.09) and shorter OS (adjusted HR 1.85; 95% CI, 1.02-3.36) among women with obesity. Conversely, no statistically significant associations were identified among nonobese women for either TTDR or OS. CONCLUSIONS Higher plasma hepcidin levels are independently associated with a significantly shorter TTDR and OS among patients with early-stage BC who are obese, but not their nonobese counterparts. Biological mechanisms underlying this finding warrant further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Department of Medicine, Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada.
- Department of Medical Oncology, Institut Régional du Cancer de Montpellier, Universite de Montpellier, Montpellier, France.
- David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.
- London Regional Cancer Program, Department of Oncology, University of Western Ontario, London, Ontario, Canada.
- Applied Statistician, Markham, Ontario, Canada.
Zitieren
APA
Cescon, E., Goodwin, P., Bobrie, A., Thezenas, S., Ganz, T., Nemeth, E., Lohmann, A., Ennis, M., Jacot, W., & Jerzak, K. J. (2026). Plasma Hepcidin as a Prognostic Biomarker in Obese and Nonobese Patients With Early Breast Cancer: A Pooled Analysis of Two Prospective Cohort Studies. Clinical Breast Cancer, 26(5), 29-35. https://doi.org/10.1016/j.clbc.2026.03.004
Vancouver
Cescon E, Goodwin P, Bobrie A, Thezenas S, Ganz T, Nemeth E, et al. Plasma Hepcidin as a Prognostic Biomarker in Obese and Nonobese Patients With Early Breast Cancer: A Pooled Analysis of Two Prospective Cohort Studies. Clinical Breast Cancer. 2026;26(5):29-35. doi:10.1016/j.clbc.2026.03.004
BibTeX
@article{Cescon2026,
author = {Cescon, Evan and Goodwin, Pamela and Bobrie, Angelique and Thezenas, Simon and Ganz, Tomas and Nemeth, Elizabeta and Lohmann, Ana and Ennis, Marguerite and Jacot, William and Jerzak, Katarzyna J},
title = {Plasma Hepcidin as a Prognostic Biomarker in Obese and Nonobese Patients With Early Breast Cancer: A Pooled Analysis of Two Prospective Cohort Studies},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {5},
pages = {29--35},
doi = {10.1016/j.clbc.2026.03.004}
}
EUVIMED